Last updated: 15 August 2024 at 5:09pm EST

Ingrid Delaet Net Worth




The estimated Net Worth of Ingrid Delaet is at least $2.35 million dollars as of 13 August 2024. Ingrid Delaet owns over 7,143 units of Neurocrine Biosciences stock worth over $304,525 and over the last 2 years Ingrid sold NBIX stock worth over $2,047,708.

Ingrid Delaet NBIX stock SEC Form 4 insiders trading

Ingrid has made over 15 trades of the Neurocrine Biosciences stock since 2023, according to the Form 4 filled with the SEC. Most recently Ingrid sold 7,143 units of NBIX stock worth $1,072,164 on 13 August 2024.

The largest trade Ingrid's ever made was selling 7,143 units of Neurocrine Biosciences stock on 13 August 2024 worth over $1,072,164. On average, Ingrid trades about 2,049 units every 22 days since 2023. As of 13 August 2024 Ingrid still owns at least 2,507 units of Neurocrine Biosciences stock.

You can see the complete history of Ingrid Delaet stock trades at the bottom of the page.



What's Ingrid Delaet's mailing address?

Ingrid's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.

Insiders trading at Neurocrine Biosciences

Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... et Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.



What does Neurocrine Biosciences do?

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders



Complete history of Ingrid Delaet stock trades at Neurocrine Biosciences

Initié
Trans.
Transaction
Prix ​​total
Ingrid Delaet
Chief Regulatory Officer
Vente $1,072,164
13 Aug 2024
Ingrid Delaet
Chief Regulatory Officer
Exercice d'option $21,572
6 Aug 2024
Ingrid Delaet
Chief Regulatory Officer
Vente $428,636
16 Jul 2024
Ingrid Delaet
Chief Regulatory Officer
Exercice d'option $21,493
1 Jul 2024
Ingrid Delaet
Chief Regulatory Officer
Exercice d'option $21,572
31 May 2024
Ingrid Delaet
Chief Regulatory Officer
Exercice d'option $21,572
6 May 2024
Ingrid Delaet
Chief Regulatory Officer
Exercice d'option $21,493
1 Apr 2024
Ingrid Delaet
Chief Regulatory Officer
Exercice d'option $517,600
21 Mar 2024
Ingrid Delaet
Chief Regulatory Officer
Exercice d'option $318,060
13 Mar 2024
Ingrid Delaet
Chief Regulatory Officer
Exercice d'option $212,040
8 Mar 2024
Ingrid Delaet
Chief Regulatory Officer
Exercice d'option $538,679
28 Feb 2024
Ingrid Delaet
Chief Regulatory Officer
Vente $95,249
13 Feb 2024
Ingrid Delaet
Chief Regulatory Officer
Vente $146,979
31 Jan 2024
Ingrid Delaet
Chief Regulatory Officer
Vente $153,861
28 Aug 2023
Ingrid Delaet
Chief Regulatory Officer
Vente $150,818
21 Aug 2023


Neurocrine Biosciences executives and stock owners

Neurocrine Biosciences executives and other stock owners filed with the SEC include: